PAC/SIR/TAC increases the ratio of Treg to Th1 and Th17 cells. (A) %CD4⁺ Tregs pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (B-C) Percentage (B) and absolute number (C) of CD4⁺ Tregs at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs recommended phase 2 dose (RP2D) PAC/SIR/TAC. (D) Graph showing the ratio of Tregs to Th1 and Th17 cells pretransplant and at days +21 and +100 on phase 2 PAC/SIR/TAC. (E) Graph demonstrating the ratio of Tregs to Th1 and Th17 cells at day +21 based on dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. ∗P < .05. NS, not significant.